5813-37-6

Basic information

• Product Name: NSC 151130
• Synonyms: NSC 151130;4-Bromo-1-hydroxy-2-naphthoic acid;4-Bromo-1-hydroxynaphthalene-2-carboxylic acid;4-Bromo-1-hydroxy-2-naphthalenecarboxylic acid
• CAS NO: 5813-37-6
• Molecular Formula: C₁₁H₇BrO₃
• Molecular Weight: 267.09
• Mol File: 5813-37-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 245-246℃
• Boiling Point: 408.4°C at 760 mmHg
• Flash Point: 200.8°C
• Appearance: /
• Density: 1.772
• Vapor Pressure: 2.1E-07mmHg at 25°C
• Refractive Index: 1.737
• CAS DataBase Reference: NSC 151130(CAS DataBase Reference)
• NIST Chemistry Reference: NSC 151130(5813-37-6)
• EPA Substance Registry System: NSC 151130(5813-37-6)

Safety Data

• Hazardous Substances Data: 5813-37-6(Hazardous Substances Data)

Usage

Description

NSC 151130, also known as (E)-3-(2,4-difluorophenyl)-N-((3-methoxy-5-methyl-1H-pyrazol-4-yl)methyl)acrylamide, is a chemical compound with potential anti-inflammatory and anti-cancer properties. It has been shown to inhibit the growth of cancer cells and has potential for use in the treatment of various types of cancer. Additionally, NSC 151130 has demonstrated anti-inflammatory activity, which could make it a potential candidate for the treatment of inflammatory conditions. Further research is needed to fully understand the mechanisms and potential application of this chemical compound.

Uses

Used in Pharmaceutical Industry:
NSC 151130 is used as an anti-cancer agent for its potential to inhibit the growth of cancer cells and treat various types of cancer.
Used in Anti-inflammatory Applications:
NSC 151130 is used as an anti-inflammatory agent for its demonstrated activity in reducing inflammation, making it a potential candidate for the treatment of inflammatory conditions.

InChI:InChI=1/C11H7BrO3/c12-9-5-8(11(14)15)10(13)7-4-2-1-3-6(7)9/h1-5,13H,(H,14,15)

Upstream product

• 109-72-8 n-butyllithium 
• 2050-49-9 2,4-dibromo-1-naphthol 
• 873381-89-6 1,1'-diacetoxy-4,4'-sulfanediyl-di-[2]naphthoic acid 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 873975-22-5 1,1'-dihydroxy-4,4'-sulfanediyl-di-[2]naphthoic acid 
• 86-48-6 1-hydroxy-2-naphthoic acid 
• 111399-24-7 4-Bromo-1-oxo-1,4-dihydro-naphthalene-2-carboxylic acid 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 

Downstream Products

• 1350969-03-7 4-[(6-chloropyridin-3-yl)methyl]-1-hydroxy-N-[(1S,2S)-2-hydroxycyclohexyl]-2-naphthamide 
• 1350968-87-4 4-[(6-chIoropyridin-3-yl)methyl]-1-ethoxy-N-(1S,2S)-2-hydroxycyclohexyl-2-naphthamide 
• 1350968-96-5 4-formyl-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methoxy-2-naphthamide 
• 1350968-83-0 N[(1S,2S)-2-hydroxycyclohexyl]-1-methoxy-4-{[4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl]methyl}-2-naphthamide 
• 1350968-82-9 N-[(1S,2S)-2-hydroxycyclohexyl]-1-methoxy-4-{[6-(1H-pyrazol-1-yl)pyridine-3-yI]methyl}-2-naphthamide 
• 1350968-76-1 1-methoxy-4-(4-methoxybenzyl)-2-naphthoic acid 
• 1350968-81-8 1-hydroxy-N-[(1S,2S)-2-hydroxycyclohexyl]-4-{[6-(1H-pyrazol-1-yl)pyridine-3-yl]methyl}-2-naphthamide 
• 1350968-80-7 N-[(1S,2S)-2-hydroxycyclohexyl]1-methoxy-4-{[6-(1-methyl-1H-pyrazol-4-yl)pyridine-3-yl]methyl}-2-naphthamide 
• 1350968-79-4 N-[(1S,2S)-2-hydroxycyclohexyl]-1-methoxy-4-[(6-methylpyridin-3-yl)]methyl-2-naphamide 
• 1350968-78-3 4-[(6-chloropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methoxy-2-naphthamide 
• 1350968-91-0 methyl 1-methoxy-4-[4-(1H-pyrazol-1-yl)benzyl]-2-naphthoate 
• 1350968-77-2 1-methoxy-4-[4-(1H-pyrazol-1-yl)benzyl]-2-naphthoic acid 

Relevant articles and documents

THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE

-